Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails

by Kinjel Shah

AbbVie (ABBV) and Allergan (AGN) announce Q4 results.

Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

by Zacks Equity Research

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

Mark Vickery headshot

Top Stock Analyst Reports for Merck, Philip Morris & American Tower

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Philip Morris International (PM) and American Tower (AMT).

Company News for Feb 11, 2020

by Zacks Equity Research

Companies in the news are: QSR, CNA, MPAA, AGN

Kinjel Shah headshot

Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates

by Kinjel Shah

Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

What's in Store for Ironwood (IRWD) This Earnings Season?

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up

by Zacks Equity Research

AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.

Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.

Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative

by Kinjel Shah

Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review

by Zacks Equity Research

The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.

Indrajit Bandyopadhyay headshot

Merck's Dificid Gets FDA Approval in Pediatric Indication

by Indrajit Bandyopadhyay

The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.

Allergan (AGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger

by Zacks Equity Research

Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.

Is Allergan (AGN) a Great Stock for Value Investors?

by Zacks Equity Research

Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

J&J Seeks Label Expansion for Spravato Nasal Spray in EU

by Zacks Equity Research

J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

Benjamin Rains headshot

3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio

by Benjamin Rains

Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...

Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

by Zacks Equity Research

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

by Zacks Equity Research

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

by Zacks Equity Research

Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

Amgen Stock Up in a Year on Pipeline & Biosimilar Progress

by Zacks Equity Research

Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.

Christopher Vargas headshot

3 Stocks with Solid Entry Points to Consider for 2020

by Christopher Vargas

Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump's airstrike killed Iran's top military commander.

Aerie's (AERI) Application for Roclanda Accepted in Europe

by Zacks Equity Research

European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.

5 Reasons Why Ironwood Stock Should Be in Your Portfolio

by Zacks Equity Research

We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.